USP <382>: Practical, audit-ready implementation guide for parenteral closure systems

Why USP <382> truly changes the rules of the game

If you work in QA/QC, Packaging Engineering, or Regulatory Affairs on injectable products, USP <382> is not “just another chapter”—it is a paradigm shift.
The standard moves the focus away from the mere chemical-physical compliance of the elastomeric component (historically covered by USP <381>) toward functional performance within the final system and under real-use conditions (fitness-for-use).

In practice: it is not enough for a stopper or plunger to be “good” in the lab. It must perform when:

• a vial is punctured multiple times (multi-dose),
• a spike remains inserted for hours,
• an autoinjector must overcome real friction forces,
• a syringe must remain intact and usable through the end of shelf life.

Scope: when USP <382> truly applies

USP <382> applies to parenteral packaging/administration systems that include primary elastomeric components (in contact with the drug product or providing container closure). Typical included examples:

• vials with elastomeric stoppers and crimp caps,
• prefilled syringes (plunger + tip cap/needle shield),
• cartridges for pens and similar systems,
• pen-injectors/autoinjectors (integrated elastomeric components),
• BFS systems with elastomeric liners,
• infusion containers with elastomeric ports.

Excluded are non-parenteral systems (e.g., nasal/inhalation).

Golden rule for QA/RA: USP <382> evaluates functionality in the context of the final system, not the “isolated stopper.”

USP <382> vs. USP <381>: what changes (without confusion)

USP <382> does not replace USP <381>. The correct logic is:

• USP <381> = base material quality (chemical-physical/biological and certain traditional stopper tests)
• USP <382> = functional suitability of the elastomeric component in the system (integrity, mechanical performance, usability)

The guide also includes a structured comparison table (see the comparison section of the guide).

What tests USP <382> requires (quick map)

USP <382> introduces or reinforces functional testing across four main categories:

System integrity (CCIT) – intact system

• Concepts: inherent integrity and maximum allowable leakage limit (MALL)
• Methodological reference: USP <1207>

Needle/spike access (for vials/ports)

• fragmentation
• penetration force
• self-sealing / in-use integrity (multi-puncture)
• spike retention & sealability

Plungers (syringes and cartridges)

• break-loose and glide forces
• plunger seal integrity

Tip cap / needle shield (syringes)

• removal force (or torque), balancing safety and usability

How to implement USP <382> in your company: a 7-phase, audit-ready workflow

Below is a 7-phase operational pathway, aligned with the guide and easily convertible into SOPs/Validation Plans.

Phase 1 — Preliminary analysis and planning

Deliverables an auditor expects to see:

• applicability assessment: which tests apply (and why some are N/A)
• risk assessment of the closure system (FMEA or equivalent)
• ownership definition: QA approves criteria and reports, RA manages dossier impact, Packaging defines design and worst-case

Common mistake: starting tests before defining intended use, number of punctures, and worst-case conditions (temperature, viscosity, aging).

Phase 2 — Selection and characterisation of elastomeric components

Goal: arrive at a “locked” component with robust data:

• supplier documentation requests (USP <381> compliance, specifications, coatings, change management)
• comparative screening (when alternatives exist)
• definition of sample pre-conditioning: sterilisation, siliconisation, assembly per final process

QA best practice: a Quality Agreement with change-notification clauses and assessment of impact on functional suitability.

Phase 3 — Functional qualification protocol (the document that “wins” inspections)

The protocol must include:

• method, minimum sample size, equipment, criteria, and rationale for each non-compendial criterion
• justification for bracketing/matrixing (if used)
• linkage to USP <1207> for integrity/leakage limits

USP <382> clarifies that some limits are not universal—in such cases, fit-for-use criteria must be defined and rationally documented.

Phase 4 — Test execution (focus on raw data and traceability)

Critical points:

• calibrated instruments with appropriate ranges (dynamometers, microscopes, leak-test systems)
• representative samples: same process, same treatments, final configuration
• particulate contamination control (appropriate environment and handling techniques)

Phase 5 — Results analysis and failure management

In case of failure:

• distinguish component/process issues from test artefacts
• open deviation/CAPA if required
• decide whether to repeat, expand sampling, or change design/component

Phase 6 — Final report (recommended structure)

The report must be CTD-ready and audit-ready:

• system and component description + conditions
• mapping to USP <382> sections
• results vs acceptance criteria
• conclusions + lifecycle recommendations (when to retest)

Phase 7 — QMS integration: SOPs, change control, routine

USP <382> becomes sustainable when embedded in the lifecycle:

• update of packaging specifications
• internal training
• change-control rule: “impact on USP <382> qualification?”
• re-evaluation plans for changes in supplier, sterilisation, formulation/viscosity, surface treatments

What FDA/EMA want to see in practice (translated into evidence)

Without theory: what convinces in audits is always the combination of:

• risk-based rationale (why those tests, why those worst cases)
• appropriate, sensitive integrity methods relative to the limit (USP <1207>)
• usability/device-compatibility data (autoinjectors: forces within user/device capability)
• change management and supplier control

FAQ

Is USP <382> mandatory if I am already compliant with USP <381>?
Yes. USP <382> is complementary and requires functional evidence within the system, not just base component quality.

How many samples are required for integrity and multi-puncture tests?
The guide typically references 30 samples per integrity test (intact system and, where applicable, in-use).

Can I use bracketing/matrixing?
Yes, if technically justified and documented, while maintaining representativeness and a sound rationale.

If you want ready-to-use templates, operational checklists, protocol outlines, practical examples (autoinjector syringe and multi-dose vial), and a step-by-step guide to make USP <382> truly implementable in your company without wasting time, see the full guide available on guidegxp.com.